News

Roanoke labs project awaits final budget approval

The intended site for 30,000 square feet of lab space is a Carilion-owned building on South Jefferson Street.

An estimated 30,000 square feet of shared lab space could go online in Roanoke within a year and a half, assuming that the General Assembly votes Wednesday to approve a compromise budget that includes nearly $16 million in state funding for the project.
The lab initiative, which was announced in December and also includes a smaller lab facility at the Virginia Tech Corporate Research Center, is designed to meet what economic development and technology leaders have for years seen as a critical need: room for researchers and entrepreneurs – especially those in the region’s burgeoning life sciences cluster – to do their work.

The intended site in Roanoke is a building on South Jefferson Street that’s owned by Carilion Clinic and is centrally located to biomedical and health science research that’s already underway in the city: It’s less than a half-mile from either the campus that houses the Virginia Tech Carilion School of Medicine and the Fralin Biomedical Research Institute or the downtown Roanoke home of RAMP, a regional technology business accelerator.

The building, which formerly housed some of Carilion’s pediatric services and is now mostly vacant, must still be fully evaluated for its suitability for the project, Carilion CFO Don Halliwill said Tuesday.

Once the General Assembly approves the budget – and the governor signs off on it – the project partners will have $15.7 million to put toward renovating the building, work that is expected to take 16 to 18 months, according to Brett Malone, president and CEO of the Corporate Research Center. The city of Roanoke is contributing another $1.9 million to the project, said Marc Nelson, the city’s director of economic development.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like